Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
2.170
+0.120 (5.85%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Vistagen Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Vistagen Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Vistagen Therapeutics.
Recommendation Trends
| Rating | Jul '23 | Aug '23 | Sep '23 | Oct '23 | Nov '23 | Dec '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 1 | 1 | 1 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $0.2 → $15 | Hold → Strong Buy | Upgrades | $0.2 → $15 | +591.24% | Dec 7, 2023 |
| Stifel | Stifel | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +453.00% | Nov 14, 2023 |
| Maxim Group | Maxim Group | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +1,282.49% | Sep 5, 2023 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $30 | Hold → Strong Buy | Upgrades | $30 | +1,282.49% | Aug 7, 2023 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 26, 2022 |
Financial Forecast
Revenue This Year
724.54K
from 1.06M
Decreased by -31.90%
Revenue Next Year
438.60K
from 724.54K
Decreased by -39.46%
EPS This Year
-1.77
from -1.52
EPS Next Year
-1.71
from -1.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.2M | 1.4M | 8.9M | |||
| Avg | 724,537 | 438,600 | 4.6M | |||
| Low | 490,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 11.6% | 87.0% | 1,925.3% | |||
| Avg | -31.9% | -39.5% | 943.3% | |||
| Low | -53.9% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.79 | -1.35 | -1.52 | |||
| Avg | -1.77 | -1.71 | -1.90 | |||
| Low | -1.73 | -2.29 | -2.17 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.